Announcement PDF Emyria ASX Announcement | 13 October 2025 ASX RELEASE. 13 October 2025 Emyria Webinar with Sharewise Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in delivering evidence- based mental health treatments, is pleased to advise that the Company will participate in a live investor webinar hosted by Sharewise on Wednesday, 15 October 2025 at 3:00 PM AEDT (Canberra, Melbourne, Sydney). Greg Hutchinson, Emyria’s Executive Chairman, and Mary-Ann Rennie, Chief Operating Officer, will provide an update on the Company’s latest developments and strategic outlook. The webinar will commence with a presentation, followed by a live Q&A session, providing attendees the opportunity to ask questions directly to Greg and Mary-Ann. Key Topics: • The problems Emyria is addressing, and the outcomes being achieved. • Why Emyria is uniquely positioned as a global leader in delivery of evidence-based treatments. • Medibank funding and national expansion of Empax programs. • Emyria’s growth strategy and upcoming milestones. All shareholders and interested investors are invited to attend the webinar. Registration details are available via the following link: https://zoom.us/webinar/register/3117599659462/WN_V5tvdRSsRY2recHWNvdfJw?utm_ campaign=Webinars&utm_medium=email&_hsmi=384529173&utm_content=384529173& utm_source=hs_email#/registration Attendees will have the opportunity to submit questions during the session. The recording will also be made available on Emyria’s Investor Hub and Company website following the event. This release has been approved by the Chairman of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com ASX RELEASE. Emyria ASX Announcement | 13 October 2025 2 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs